Skip to content

A randomized trial of electrical stimulation of the brain for management of psychogenic seizures

Safety and efficacy of transcranial direct current stimulation (tDCS) as add on therapy in reducing event frequency in subjects with psychogenic non-epileptic seizures: A randomized double blind sham controlled trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/061260
Enrollment
36
Registered
2024-01-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F445- Conversion disorder with seizuresor convulsions

Interventions

Intervention1: TRANSCRANIAL DIRECT CURRENT STIMULATION: Application of tDCS and sham stimulation to intervention arm and placebo arm respectively, for 5 days two of 20mins stimulation per day Control

Sponsors

NONE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: Subjects with psychogenic non-epileptic seizures 1. Aged >18 years 2. Diagnosis of PNES by short term VEEG recording 3. >=2 events/month.

Exclusion criteria

Exclusion criteria: 1)Subjects with known epilepsy 2)Subjects with PNES who have significant intellectual disability 3)Severe psychiatric comorbidity and suicidal ideations 4)Pregnant women 5)Those with dementia, psychosis, delirium, scalp infections or lesions 6)Subjects with history of brain surgery or aneurysm clipping or electrical device implantation like pacemaker

Design outcomes

Primary

MeasureTime frame
defined as success if â?¥ 50% reduction in event frequency at end of one month compared to baseline. Timepoint: defined as success if â?¥ 50% reduction in event frequency at end of one month compared to baseline.

Secondary

MeasureTime frame
Absolute number of events/months at the end of 1,2 & 3 months expressed as median with IQR or mean with SD. Application of 1st sessions of tDCS is considered as day 1. After 30 days from the onset of tDCS patient first time followed and subsequently at 2nd and 3rd month; Safety parameters from the ADR and self-report questionnaire as proportions; Scores on HAM-A, HAM-D, BREF-QOL, QOLIE at the end of 1, 2 and 3 months as median with IQR. Timepoint: at end of 2nd & 3rd month

Countries

India

Contacts

Public ContactDr Sowmya S

Jawaharlal Institute of Postgraduate Medical Education and Research

rajeswari.a@gmail.com9790209240

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026